BUZZ-Amgen stock falls as Repatha gets direct sales price cut
Reuters
3 hours ago
BUZZ-Amgen stock falls as Repatha gets direct sales price cut
** Amgen AMGN.O on Mon launched direct-to-consumer U.S. sales of cholesterol drug Repatha at discount $239/mo cash price; stock down 1.4% ** Move responds to U.S. political pressure to lower drug prices; new price nearly 60% below list, but only for uninsured cash buyers ** AMGN says 98% of insured U.S. patients already get Repatha with co-pays as low as $15 ** Repatha sales hit $2.2 bln last yr** AMGN stock up ~13% YTD, lagging Nasdaq .IXIC rise of 19%
(Reporting by Noel Randewich)
((noel.randewich@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.